Seiki Co., Ltd.
Letter data
- Company
- Seiki Co., Ltd.
- Recipient
- Seiki Co., Ltd. | United States
- Issue date
- 2018-03-28
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- 523744
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Seiki Co., Ltd.
MARCS-CMS 523744 —
March 28, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Recipient:
Seiki Co., Ltd.
United States
Issuing Office:
United States
5001 Campus Drive
College Park, MD 20740
March 28, 2018
Mr. Kenji Kuroiwa
President
Seiki Co., Ltd.
7922-3 Kiire Maenohama-Cho
Kagoshima City, Kagoshima Prefecture
Japan 891-0205
Dear Mr. Kuroiwa:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter #523744, issued June 1, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Maria Corpuz
Team Leader
Food Adulteration Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety
and Applied Nutrition
Content current as of:
04/02/2018